<DOC>
	<DOCNO>NCT00764738</DOCNO>
	<brief_summary>Visual outcome use monthly ranibizumab therapy well establish clinical trial , best way assess treat patient PRN therapy proven . Information lack Multi-focal ERG microperimetry outcome ranibizumab therapy . Additionally , VA OCT outcomes n't always correlate assessment Multi-focal ERG microperimetry may useful early predictor patient retreat . This study assess 2 group ( monthly PRN therapy ) ass high resolution OCT , microperimetry , Multi-focal ERG outcome . For PRN group retreatment base OCT criterion . We investigate microperimetry multifocal ERG would early predictor fluid recurrence .</brief_summary>
	<brief_title>Study Investigating OCT , Multifocal ERG , Microperimetry Monthly Versus PRN Ranibizumab Neovascular Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study . Age great equal 50 year old . Patients active neovascular AMD Pregnancy ( Positive pregnancy test ) lactation . Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch . Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial Concurrent eye disease study eye could compromise visual acuity ( e.g. , diabetic retinopathy , advanced glaucoma ) Previous PDT therapy Previous intravitreal steroid therapy within last 3 month Previous antiVEGF therapy past month</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>ARMD</keyword>
	<keyword>AMD</keyword>
	<keyword>exudative AMD</keyword>
</DOC>